!! History Commons Alert, Exciting News
Bayer was a participant or observer in the following events:
The Sunday Times reports that an inquiry has been launched into the behavior of Bayer, after revelations in a British trial regarding the anthrax antibiotic drug Cipro. The drug has been tested on hundreds despite the company having conducted studies which showed it reacted badly with other drugs, seriously impairing its ability to kill bacteria. These results are kept secret. Nearly half of those on whom the drug was tested at one test center develop a variety of potentially life-threatening infections, while data at other test centers is unknown. [Sunday Times (London), 5/14/2000]
The FDA endorses the use of Bayer’s Cipro drug to prevent inhalation anthrax. [Reuters, 7/28/2000] An official recommendation like this is highly unusual for the FDA. A 1997 Pentagon study of anthrax in rhesus monkeys showed that several other drugs were as effective as Cipro. The reason given for only recommending Cipro is the government wants a weapon against anthrax should it come up against a strain resistant to drugs in the penicillin and tetracycline families of antibiotics. [New York Times, 10/21/2001] The pharmaceutical industry spent $177 million on lobbying in 1999 and 2000—more money than any other industry. The FDA has been accused of conflicts of interest with companies including Bayer. [New York Times, 11/4/2001]
The Canadian government overrides Bayer’s patent for the anthrax antibiotic Cipro and orders a million tablets of a generic version from another company. The US government says it is not considering a similar move. Patent lawyers and politicians state that adjusting Bayer’s patent to allow other companies to produce Cipro is perfectly legal and necessary. [New York Times, 10/19/2001] The New York Times notes that the White House seems “so avidly to be siding with the rights of drug companies to make profits rather than with consumers worried about their access to the antibiotic Cipro,” and points out huge recent contributions by Bayer to Republicans. [New York Times, 10/21/2001]
The Bayer Corporation, holders of the US patent on the anthrax antibiotic Cipro, agrees with the US to reduce the price of Cipro in the US from $1.83 to 95 cents. Analysts say the price reduction will reduce Bayer’s profit margin from 95% to 65%. This reduction applies only to sales to the US government, not sales to the public. [New York Times, 11/4/2001] Bayer has allowed no other companies to produce or import Cipro into the US. Other countries with less stringent patent laws sell Cipro for 1/30th the US price, and have offered to import large quantities into the US. [New York Times, 10/21/2001] Nevertheless, a class action suit by over one million Americans has been filed against Bayer and two other companies, alleging that Bayer has paid $200 million to two competitors to not make generic versions of Cipro. [Lieff Cabraser Heimann & Bernstein, 10/25/2001] The profits from Cipro are considered a “lifesaver” for Bayer, which had been considering pulling out of pharmaceuticals altogether. [Guardian, 10/31/2001]
St. Louis Federal District Judge Rodney W. Sippel allows an antitrust case against Monsanto Company, Bayer, Syngenta, and Pioneer seed companies to proceed. According to the lawsuit, which was filed in 1999 (see March 15, 2001), documents show that the companies conspired during the late 1990s to fix prices and control the seed market. The second part of the lawsuit—which blames the companies for the huge losses suffered by farmers because of global opposition to genetically modified crops—is dismissed. [New York Times, 9/24/2003] Judge Sippel was once listed as one of three lawyers defending Monsanto in a similar case. [Guardian, 1/10/2004]
Agriculture Secretary Mike Johanns announces that US commercial supplies of long-grain rice were inadvertently contaminated in 2005 with a genetically modified variety (LLRICE 601) developed by Bayer CropScience that has not been approved for human consumption. Johanns says the Department of Agriculture believes the “product is safe.” LLRICE 601 contains bacterial DNA that makes it resistant to a weedkiller manufactured by Aventis. Johanns also says that Bayer now has plans to seek FDA approval for LLRICE 601. [Washington Post, 8/19/2006] News of the contamination sends US rice futures plummeting as European grocery stores begin pulling US rice from their shelves. The European Union says it will only accept US long-grain rice that has been certified GM-free. [USA Today, 10/23/2006] Similarly, Japan announces that it is suspending long grain rice imports and warns that if there is another incident of GM contamination, it will reject all US imports. [Associated Press, 10/29/2006]
Receive weekly email updates summarizing what contributors have added to the History Commons database
Developing and maintaining this site is very labor intensive. If you find it useful, please give us a hand and donate what you can.
If you would like to help us with this effort, please contact us. We need help with programming (Java, JDO, mysql, and xml), design, networking, and publicity. If you want to contribute information to this site, click the register link at the top of the page, and start contributing.